Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Creciendo
La empresa se encuentra en una fase de crecimiento. Sus ingresos anuales más recientes ascienden a 52.74M USD.
Giro hacia las pérdidas
El rendimiento de la empresa ha pasado a ser deficitario. Sus pérdidas anuales más recientes han sido de dólares estadounidenses.
Valorada de forma justa
El PE más reciente de la empresa es 12.42, en un rango percentil medio de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 19.91M acciones, lo que supone un aumento del 9.74% con respecto al trimestre anterior.